SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

China Accepts Review of Innovent Sintilimab Combination for Advanced Melanoma

China has accepted for review a combination of Innovent’s sintilimab and GC101 for advanced melanoma.

Related stories